Clinical Trials Search Tool

Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents

Disease/Condition: Bacterial Meningitis, MenABCWY combination vaccine

Location: Gresham

Ages: 11-14 years + 364 days

Enrollment Opens: 02-01-2022

Enrollment Closes: TBD

Description:

A Phase IIb, Randomized, Observer-Blind study to
Describe the Safety, Tolerability, and
Immunogenicity of MenABCWY Administered on
Different Dosing Schedules in Healthy Adolescents

Study ID: 215344 (MENABCWY-020)

To Enroll: Contact Cyn3rgy Research at; 503-907-2179 ext. 2 or visit us on the web at http://www.cyn3rgy.com

Posted by: Cyn3rgy Research | http://www.cyn3rgy.com